{
    "nct_id": "NCT03677154",
    "official_title": "A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma",
    "inclusion_criteria": "Inclusion Criteria for All Cohorts\n\n* At least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest diameter\n* Adequate hematologic function\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2; with the exception of South Korea, where participants 80 years or older with ECOG >/= 2 will not be eligible\n\nInclusion Criteria Specific to Cohort A\n\nParticipants in Cohort A must also meet the following criteria for study entry:\n\n* Histologically confirmed DLBCL according to World Health Organization (WHO) 2016 expected to express the cluster of differentiation-20 (CD20) antigen\n* One prior therapy with any systemic anthracycline-based chemoimmunotherapy containing regimen for previously untreated DLBCL\n* Best response of SD or PR to prior systemic chemoimmunotherapy at the end of induction treatment in accordance with the Lugano 2014 criteria\n\nInclusion Criteria Specific to Cohorts B and C\n\nParticipants in Cohorts B and C must also meet the following criteria for study entry:\n\n* Previously untreated, histologically confirmed, DLBCL according to WHO 2016 classification\n* Age >/= 80 years, or\n* Age 65-79 years and considered ineligible for chemoimmuotherapy (R-CHOP) with at least one of the following: Impairment in at least two activity of daily living (ADL) components as defined in the protocol; impairment in at least two instrumental ADL components as defined in the protocol; cumulative illness rating scale - geriactic (CIRS-G) score of at least one cormorbidity with a severity score of 3-4 (not including lymphoma and hematologic deficiencies due to lymphoma) or a score of 2 in >/= 8 comorbidities; impairment in cardiac function, renal function, liver function, or other comorbidities such that the participant is unfit for full-dose immunochemotherapy, such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)\n* Participants with an initial ECOG performance status of 3 may be considered during screening if the performance status is DLBCL-related and if pre-phase treatment during the screening phase (not more than 100 mg/day up to 7 days prior to Cycle 1 Day 1) results in an improvement of ECOG performance status to </= 2 prior to enrollment\n\nExclusion Criteria for All Cohorts\n\nParticipants who meet any of the following criteria will be excluded from study entry:\n\n* Transformed lymphoma\n* CNS lymphoma\n* Prior treatment with mosunetuzumab\n* Prior stem cell transplant (autologous and allogeneic)\n* History of confirmed progressive multifocal leukoencephalopathy (PML)\n* Known or suspected chronic active Epstein Barr virus (CAEBV), hepatitis B, hepatitis C (HCV), or Human Immunodeficiency Virus (HIV)\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Positive SARS-CoV-2 antigen or PCR test within 30 days prior to Cycle 1 Day 1\n* Prior solid organ transplantation\n* Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Clinically significant history of liver disease\n* Prior treatment with radiotherapy within 2 weeks prior to Cycle 1, Day 1 (C1D1)\n* Significant cardiovascular disease\n\nExclusion Criteria Specific to Cohort A\n\nParticipants in Cohort A who meet the following criteria will be excluded from study entry:\n\n- Prior anti-lymphoma treatment with chemotherapy, immunotherapy, or biologic therapy 4 weeks prior to C1D1\n\nExclusion Criterion Specific to Cohorts B and C\n\nParticipants in Cohorts B and C who meet the following criterion will be excluded from study entry:\n\n- Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy\n\nExclusion Criteria Specific to Cohort C\n\nParticipants in Cohort C who meet the following criteria will be excluded from study entry:\n\n- Current Grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}